Business
Novo Nordisk and Eli Lilly have been battling head-to-head in an exploding obesity market. They should never have been compared apples to apples.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
This year marked yet another series of interesting, exciting and occasionally puzzling stories coming out of the biopharma industry. Our breaking news writers, Alex Keown and Mark Terry, picked their top 10 stories of the year.
Pharma and life sciences companies bolster their leadership teams and boards with this week’s Movers & Shakers.
Pfizer handed over $10 million in upfront money and dangled a potential $240 million more if the program hits certain development and sales milestones.
Sarepta Therapeutics and Roche inked a licensing deal that gives Roche exclusive commercial rights to SRP-9001, Sarepta’s investigation gene therapy for Duchenne muscular dystrophy, outside the U.S.
The U.S. Government is increasing the measures it is taking to counter what it sees as a growing threat to scientific intellectual property from China.
Less than a month after snagging approval for a first-of-its-kind sickle cell disease treatment, Global Blood Therapeutics (GBT) is already looking at next-generation measures to tackle the disorder, as well as other diseases of the blood such as beta thalassemia.
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, announced that it established a Scientific Advisory Board for its Corporate Research activities.
Evotec SE announced plans to extend its sample management activities through an expansion of its service agreement with Sanofi.
Vaccitech Ltd announced that its strategic collaboration with the Ludwig Institute for Cancer Research, Vaccitech Oncology Limited, has entered into a clinical partnership with Cancer Research UK to develop VOLT’s VTP-600 immunotherapy as a treatment option for patients with non-small cell lung cancer.
The company will utilize their new headquarters for more efficient distribution and expanded capabilities